Printer Friendly

CYTOMED, INC. EXPANDS SCIENTIFIC TEAM -- ADDS SENIOR DIRECTOR, MEDICINAL CHEMISTRY AND PRINCIPAL SCIENTIST

 CAMBRIDGE, Mass., May 11 /PRNewswire/ -- CytoMed, Inc. today announced that it has appointed Tesfaye Biftu, Ph.D., formerly of Merck & Co., Inc., to senior director, medicinal chemistry and Paul J. Higgins, Ph.D., formerly of Repligen Corp., to principal scientist.
 "Dr. Biftu's expertise in medicinal chemistry and Dr. Higgins' extensive research background in cell biology will add significantly to CytoMed's scientific team," commented Thomas R. Beck, M.D., chairman and chief executive officer of CytoMed. "We are pleased these outstanding scientists have joined us, and look forward to their many contributions as we develop pharmaceuticals for the treatment of inflammatory and immune system disorders."
 Biftu comes to CytoMed following a 12-year tenure with Merck, serving most recently as senior research fellow. Biftu received his Ph.D. in organic/natural product chemistry from Brandeis University, his MBA in management from Rutgers University and his M.Sc. in chemistry and B.A. in economics from Western Michigan University.
 Higgins joins CytoMed from Repligen Corp., where since 1989 he was research scientist in the department of immunology. Prior to that he was research fellow in medicine at the Massachusetts General Hospital. From 1977-1987, Higgins held positions at Harvard Medical School, Boston University, the University of Delaware and Brigham and Women's Hospital. He holds a Ph.D. in cell biology from Boston University, an M.S. in marine biology from the University of Delaware and a B.S. in biology/geology from the University of Rochester.
 CytoMed is engaged in the discovery, development and commercialization of novel, proprietary treatments for disorders involving inflammation and the immune response. CytoMed's technology offers the potential for revolutionizing the treatment of inflammatory and immune systems disorders based on the development of pharmaceuticals having new mechanisms of action. The company's headquarters are located in Cambridge, Mass.
 -0- 5/11/93
 /CONTACT: Thomas R. Beck, M.D., chairman and CEO, CytoMed, Inc., 617-661-3400; Lynne H. Brum of Feinstein Partners Inc., 617-577-8110, for CytoMed/


CO: CytoMed, Inc. ST: Massachusetts IN: MTC SU: PER

DJ -- NE004 -- 6852 05/11/93 08:30 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 11, 1993
Words:341
Previous Article:SYMBOL TECHNOLOGIES INTRODUCES NEW HANDS-FREE SCANNER FOR PDF417 AT ID EXPO; EIGHT COMPANIES ANNOUNCE PDF417-COMPATIBLE PRODUCTS
Next Article:EPIGEN REPORTS QUARTER FINANCIAL RESULTS
Topics:


Related Articles
CEPHALON APPOINTS NEW SCIENCE ADVISORY BOARD MEMBER
STEVE E. REESE JOINS CYTOMED AS VICE PRESIDENT, BUSINESS DEVELOPMENT
CYTOMED PROMOTES MICHAEL E. FITZGERALD TO VICE PRESIDENT, CHIEF FINANCIAL OFFICER
PHYTERA, INC. ANNOUNCES KEY MANAGEMENT, SCIENTIFIC APPOINTMENTS
CYTOMED AND STIEFEL LABORATORIES FORM COLLABORATION FOR CMI-392, A TOPICAL TREATMENT FOR INFLAMMATORY SKIN DISORDERS
TO BUSINESS AND TECHNOLOGY EDIOTRS:
CytoMed Appoints Richard Woodrich Executive Vice President and COO
James P. Feeney Joins Vertex Pharmaceuticals as Senior Director of Business Development
UCB Pharma Expands Scientific Presence in the U.S.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters